Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CLRB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Glutathione Disulfide NOV-002 | Non Small Cell Lung Cancer | Phase 3 · NCT00347412 | Completed |
| Iodine I 131 Iopofosine | Waldenstrom Macroglobulinaemia | Phase 3 · NCT07766421 | Not yet recruiting |
| Cyclophosphamate | Waldenstrom Macroglobulinaemia | Phase 3 · NCT07766421 | Not yet recruiting |
| Iodine I 124 Iopofosine | Glioblastoma | Phase 2 · NCT01898273 | Terminated |
| NOV-205 | Hepatitis C | Phase 2 · NCT01058512 | Completed |
| I124-NM404 | Non Small Cell Lung Cancer | Phase 1 · NCT00582283 | Completed |
| Iodine I 125 Iopofosine | Breast Cancer | Phase 1 · NCT07311993 | Recruiting |
Also used in these trials (approved or third-party drugs, not CLRB's own candidates): Carboplatin, Rituximab, Paclitaxel, Dexamethasone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
CLRB holds $24.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.7M/quarter from operations, an estimated runway of 9.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 90 · High
These uncertainties raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CLRB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| BALYASNY ASSET MANAGEMENT L.P. | Institution (13G, 5%+) | 944,265 | 9.41% | 2026-09-30 |
| Empery Asset Management, LP | Institution (13G, 5%+) | 864,090 | 8.61% | 2026-06-30 |
| Stonepine Capital Management, LLC | Institution (13G, 5%+) | 863,277 | 8.60% | 2026-05-04 |
| SilverArc Capital Management, LLC | Institution (13G, 5%+) | 851,285 | 8.48% | 2026-06-30 |
| StemPoint Capital LP | Institution (13G, 5%+) | 845,740 | 8.42% | 2026-06-30 |
| Bleichroeder LP | Institution (13G, 5%+) | 808,300 | 8.05% | 2026-06-30 |
| JANUS HENDERSON GROUP PLC | Institution (13G, 5%+) | 798,382 | 7.95% | 2026-05-29 |
| Caligan Partners LP | Institution (13G, 5%+) | 469,998 | 4.68% | 2026-06-30 |
| Rosalind Advisors, Inc. | 5%+ holder (13G) | 247,715 | 2.47% | 2025-12-31 |
| Andrei Shustov Senior Vice President, Medical · +260,000 options |
Insider | 55,038 | 0.55% | 2023-12-08 |
| Darrell Shane Lea Chief Commercial Officer · +360,000 options |
Insider | 39,599 | 0.39% | 2023-06-23 |
| Jarrod Longcor Chief Operating Officer · +1.31M options |
Insider | 20,451 | 0.20% | 2026-05-07 |
Share count 10,039,183 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CLRB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →